Last updated 2026-09-04
- Raised $500M convertible note, Nov 2020
- Went public on NASDAQ (NVCR), Oct 2015
- Raised $150M debt round, Nov 2020
Total raised
$800.0M
Last: Public Offering 2020-11
Stage
Public
Founded
2000
Headcount
1,630
HQ
Haifa, Israel
Sector
Health Tech & Life Sciences
About
NovoCure is a global oncology company focused on extending survival in aggressive forms of cancer through its proprietary Tumor Treating Fields (TTFields) therapy. TTFields therapy uses low-intensity, intermediate-frequency alternating electric fields to disrupt cancer cell division. The company's commercialized products, including Optune Gio, Optune Lua, and Optune Pax, are approved in certain countries for the treatment of glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma, and locally advanced pancreatic cancer. NovoCure conducts research and development in Haifa, Israel, and has operations across North America, Europe, the Middle East, and Asia.
Funding history · 6 rounds · $800.0M total
7 events/rounds · $800.0M Total Funding: $165.0M in Public Equity, $800.0M in Debt
Nov 2020
Convertible Debt
$500.0M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Nov 2020
Debt Financing
$150.0M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Feb 2018
Debt Financing
$150.0M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Sep 2009
A Round
Undisclosed
tracxn.com
★ Index Ventures★ Johnson & Johnson Innovation – JJDC
2003
★ WFD Ventures LLC
2000
★ Lennart Perlhagen
Headcount over time
1,630 employees (2026-09) · 1 point
Offices
Haifa, Israel · HQ / main office
Show all offices (7 more)
- Mnchen, Germany
- Saint Helier, Jersey
- New York, United States
- Malvern, United States
- Japan
- Root, Switzerland
- Portsmouth, United States
Q&A
- What is Novocure's primary therapy for solid tumor cancers?
- Novocure develops and commercializes Tumor Treating Fields (TTFields) therapy, which uses low-intensity, intermediate-frequency alternating electric fields to disrupt cancer cell division.
- When did Novocure go public and on which exchange?
- Novocure went public on NASDAQ in October 2015, raising $165 million through its public offering.
- What was a key leadership change announced in September 2024?
- In September 2024, Novocure announced a planned CEO transition, with Asaf Danziger retiring and CFO Ashley Cordova named as his successor.
- What recent FDA approval did Novocure receive for its Optune Lua device?
- In October 2024, Novocure's Optune Lua received FDA approval for the treatment of metastatic non-small cell lung cancer.
- What was a significant development regarding Novocure's pancreatic cancer therapy in December 2024?
- In December 2024, Novocure announced positive topline results from its Phase 3 PANOVA-3 clinical trial of Tumor Treating Fields (TTFields) therapy for pancreatic cancer.
- What was a notable FDA approval for Novocure in February 2026?
- In February 2026, the U.S. FDA approved Novocure’s Optune Pax® for the treatment of locally advanced pancreatic cancer.
- What was the outcome of Novocure's Phase 3 TRIDENT trial for newly diagnosed glioblastoma in June 2026?
- In June 2026, Novocure announced that the Phase 3 TRIDENT trial evaluating earlier use of Tumor Treating Fields therapy in newly diagnosed glioblastoma did not meet its primary endpoint.
Team · 17
Yoram Palti
Founder · Founder, CTO
Frank Leonard
Chief Executive Officer
Barak Ben-Arye
General Counsel
Mukund Paravasthu
Chief Operating Officer
Uri Weinberg
Chief Medical & Innovation Officer
William F. Doyle
Executive Chairman
Christoph Brackmann
Chief Financial Officer
Michael Puri
Chief Human Resources Officer
Asaf Danziger
Board Member
Kinyip Gabriel Leung
Director
Jeryl Hilleman
Director
David T. Hung
Director
Martin J. Madden
Director
Allyson J. Ocean, M.D.
Director
Timothy J. Scannell
Director
Kristin Stafford, CPA
Director
William A. Vernon
Director
Sectors & technology
Primary sector
Health Tech & Life Sciences
Technologies
Target customers
Business model
B2B
Highlights
1 Patents
Tags
cell-therapycancernon-invasivemedical-technologieschemotherapyoncologypharmaceuticalstreatmentswearable
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
Identifiers & details
| Legal name | NovoCure Limited |
|---|---|
| Founded | 2000 |
| Employees (exact) | 1630 |
| Offices | Mnchen; Saint Helier; New York; Malvern; Japan; Root; Portsmouth |
| Market cap | $1.4B |
| Status reason | Public on NASDAQ on Oct, 2015 |
| Wikidata QID | Q30267502 |
Acquisitions & public offerings
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| IPO | 2015-10 | NASDAQ | NVCR | $165.0M |
Radar intelligence
Patents
| EPO | 375 |
|---|
Publications (Crossref)
| Works | 10 |
|---|
App Store
| App | Rating | Ratings |
|---|---|---|
| MyNovocure | 3.42857 |
Web history (Wayback)
| Domain | novocure.com |
|---|
Wikidata
| QID | Q30267502 |
|---|
Certificate / subdomain footprint
| Subdomains | 87 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 512768003 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 1999-04-15 |
| Purpose | לעסוק בסוגי עיסוק שפורטו בתקנון |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2026 |
| Active charges / liens | 0 |
| Registry events | 1 — annual_report (1) |
| Registered address | חת נחום 5 טירת כרמל |
Recent registry events
| Date | Event |
|---|---|
| 2026-07-15 | דו~ח שנתי-עדכון כתובת |